KAZM Pharmaceuticals is an innovative pharmaceutical company specializing in the topical delivery of medicines to address critical healthcare challenges, including pain management, the opioid crisis, infections, antibiotic resistance, and vector-borne diseases.
At KAZM, we are a multidisciplinary team of experts driven by a shared passion for innovation and excellence in healthcare.
Our group combines the expertise of scientists, pharmacists, biotechnologists, and orthopedic surgeons, leveraging diverse perspectives to develop groundbreaking solutions that improve patient outcomes worldwide.
We are dedicated to developing solutions that make a meaningful impact on patients' lives.
Our team unites the strengths of scientists, pharmacists, biotechnologists, and orthopedic surgeons to deliver comprehensive and innovative healthcare solutions.
We harness cutting-edge technologies to develop treatments that redefine standards of care.
Every decision we make is driven by our commitment to improving lives and addressing unmet medical needs.
These guiding principles ensure our products consistently meet the highest standards of quality, safety, and performance.
At KAZM Pharmaceuticals, our commitment to advancing medical science is exemplified by our active Phase III clinical trial evaluating the safety and efficacy of our topical pain cream. This critical step demonstrates our dedication to rigorous research and our focus on delivering high-quality, evidence-based therapies.
| Trial Overview | Details |
|---|---|
| Study Title | Phase 3 Blinded Randomized Controlled Trial - Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty |
| Regulatory Approvals |
Health Canada Clinical Trial Control #: 287614 ClinicalTrials.gov ID: NCT06202989 Link to trial |
| Primary Outcome | Pain reduction |
| Secondary Outcomes |
|
| Patient Enrollment | Ongoing (288 patients; fully powered for primary outcome measure) |
| Estimated Completion Date | Winter 2025 |
| Trial Overview | Details |
|---|---|
| Study Title | Phase 3 Crossover Randomized Controlled Trial - Multiprofen-CC to Reduce Pain in Hand Arthritis |
| Regulatory Approvals | Health Canada Clinical Trial Control #: 297848 ClinicalTrials.gov ID: NCT06202989 Link to trial |
| Primary Outcome | Pain reduction |
| Secondary Outcomes |
|
| Patient Enrollment | Ongoing (88 patients; fully powered for primary outcome measure) |
| Estimated Completion Date | Spring 2026 |
At KAZM Pharmaceuticals, innovation is at the heart of everything we do, and our commitment to groundbreaking research is reflected in our robust intellectual property portfolio.
Two in the United States and two in Canada, covering proprietary formulations and novel delivery mechanisms for topical pain relief and related applications. These patents reinforce our leadership in developing cutting-edge solutions to address pain management and other critical healthcare challenges.
As a new and innovative pharmaceutical company, we are committed to advancing healthcare solutions. Whether you're looking for information about our products or have general questions about our company, our team is ready to help.